BREAST CANCER:
NEW HORIZONS, CURRENT
CONTROVERSIES

July 10–12, 2014
Long Wharf Marriott
Boston, MA



Breast Cancer: New Horizons, Current Controversies encompasses the full range of breast cancer care from the pathogenesis of disease to the barriers that prevent breast health care. Innovative developments in cell biology, genetics, treatment strategies and surgical techniques offer new opportunities for diagnosing, treating, and defeating breast cancer but may lead to comprehension and knowledge gaps for the target audience.

The primary goal of Breast Cancer: New Horizons, Current Controversies is to assist health care professionals who care for breast cancer patients to integrate evidence-based information into their practices so that they might reduce the disparities in breast cancer screening, diagnosis, treatment and monitoring. This engaging three-day course will offer a rare convergence of clinical experts in medical, surgical, and radiation oncology who will reinforce a multidisciplinary approach to translating scientific knowledge into practical applications in medicine. Interactive learning formats such as group case discussions, Q&A and panel presentations will assist clinicians in solving challenging clinical cases, address controversial topics, and offer practical treatment strategies.

LEARNING OBJECTIVES

Upon completion of this course, participants will be able to:

  • Identify the molecular heterogeneity of breast cancer and therapeutic implications of HER2+, Triple Negative, and ER+ disease.
  • Evaluate the genetic and personal risk factors of breast cancer and the relationship to prevention, and evaluate the various methods of genetic testing.
  • Implement current prevention, survivorship, and symptom management approaches to improve outcomes and quality of life for individuals with breast cancer or at increased risk.
  • Assess challenging clinical cases in the adjuvant and metastatic breast cancer settings through different professional perspectives.
  • Grade clinical trial results for their potential impact on diagnosis, management and treatment of breast cancer.
  • Incorporate strategies to improve breast cancer early detection, local therapy and treatment for patients with breast cancer or individuals with increased risk.

WHO SHOULD ATTEND

Specific learners include Medical Oncologists, Surgical Oncologists, Breast Surgeons, Radiation Oncologists, Registered Nurses, Nurse Practitioners, and other clinicians interested in the care of women and men with breast cancer.

ACCREDITATION

The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Harvard Medical School designates this live activity for a maximum of 21 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Royal College of Physicians and Surgeons of Canada recognizes conferences and workshops held outside of Canada that are developed by a university, academy, hospital, specialty society or college as accredited group learning activities.

AMA PRA Category 1 Credits™ claimed by physicians attending live events certified and organized in the United States for AMA PRA Category 1 Credits™ can be claimed through the agreement on mutual recognition of credits between UEMS and AMA, considered as being equal to the European Continuous Medical Education Credits (ECMEC©) granted by the UEMS. One AMA PRA Category 1 Credit™ is equivalent to one (1) hour of European EACCME Credit (ECMEC©), therefore up to 21 ECMEC© Credits are available. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Nursing contact hours for some sessions have been applied for.
Dana-Farber Cancer Institute is an approved provider (#PA-156) of continuing nursing education by the Massachusetts Association of Registered Nurses' Credentialing Center's Commission on Accreditation.

PROGRAM SCHEDULE*

THURSDAY, JULY 10, 2014
7:50 – 8:00Welcoming Remarks
Harold Burstein, MD, PhD,
Dana-Farber/Brigham and Women's Cancer Center
8:00 – 9:55 Session I: Management of the Axilla
Moderator: Barbara Smith, MD, PhD; Massachusetts General Hospital Cancer Center
8:00 – 8:30 Axilla Imaging: Who and How?
Pamela DiPiro, MD;
Dana-Farber/Brigham and Women's Cancer Center
8:30 – 9:00 Regional Node Radiation: When and How?
Jennifer Bellon, MD;
Dana-Farber/Brigham and Women's Cancer Center
9:00 – 9:30 Lymphedema After Treatment for Breast Cancer:
A New Approach to an Old Problem
Alphonse Taghian, MD; Massachusetts General Hospital Cancer Center
9:30 – 9:45 Q&A
9:45 – 9:55 Break
9:55 – 12:25 Session II: Local Therapy
9:55 – 10:25 Margins: How Much is Enough?
Stuart Schnitt, MD; Beth Israel Deaconess Medical Center
10:25 – 10:55 Radiation Management for DCIS
Abram Recht, MD; Beth Israel Deaconess Medical Center
10:55 – 11:25 Lecture Is DCIS Cancer? Implications of a Name
in the Management of a Disease
Shelley Hwang, MD; Duke Medical Center
11:25 – 12:25 Tumor Board: Advanced Stage Breast Cancer
Moderator: Craig Bunnell, MD, MPH, MBA;
Dana-Farber/Brigham and Women's Cancer Center
12:25 – 1:25 Lunch on your own
1:25 – 3:20 Session III: Global Issues of Breast Cancer Epidemiology,
Screening, and Care

Moderator: Lawrence Shulman, MD; Dana-Farber/Brigham and Women's Cancer Center
1:25 – 1:55 Global Trends in Breast Cancer Heterogeneity-Etiology and Implications
William Anderson, MD, MPH; National Cancer Institute
1:55 – 2:25 Mammography Screening In High Resource Countries –
To Screen Or Not To Screen
Wendy Chen, MD, MPH;
Dana-Farber/Brigham and Women's Cancer Center
2:25 – 2:55 Confronting the Global Breast Cancer Burden –
Strategies for Diagnosis and Treatment
Lawrence Shulman, MD;
Dana-Farber/Brigham and Women's Cancer Center
2:55 – 3:10 Q&A
3:10 – 3:20 Break
3:20 – 5:35 Session IV: Symptom Management
Moderator: Lidia Schapira, MD;
Massachusetts General Hospital Cancer Center
3:20 – 3:50 Neurocognitive Side Effects of Breast Cancer Therapy:
What are They and How to Recognize Them
Mary-Ellen Meadows, PhD;
Dana-Farber/Brigham and Women's Cancer Center
3:50 – 4:20 Management of Menopausal Symptoms
and Sleep Disorders in Breast Cancer Patients
Hadine Joffe, MD, MSc;
Dana-Farber/Brigham and Women's Cancer Center
4:20 – 4:50 Management of Treatment-Induced Neuropathy:
Practical Tips for Clinicians
Janet Abrahm, MD; Dana-Farber/Brigham and Women's Cancer Center
4:50 – 5:20 Exercise and Diet for Breast Cancer
Jennifer Ligibel, MD; Dana-Farber/Brigham and Women's Cancer Center
5:20 – 5:35 Q&A
5:35 Networking Reception
FRIDAY, JULY 11, 2014
8:00 – 8:30Lecture: The Axilla After Preoperative Therapy
Monica Morrow, MD, FACS; Memorial-Sloan Kettering Cancer Center
8:30 - 10:55 Session V: HER2+ Disease
Moderator: Shom Goel, MD, PhD; Dana-Farber/Brigham and Women's Cancer Center
8:30am – 9:00am Updates on HER2 Testing: The ASCO/CAP Guidelines and Beyond
Antonio Wolff, MD; Johns Hopkins Medicine
9:00 – 9:30 Innovations in HER2+ Directed Therapy for Early
and Advanced Stage Breast Cancer
Ian Krop, MD, PhD; Dana-Farber/Brigham and Women's Cancer Center
9:30 – 9:40 Break
9:40 – 10:10 Neoadjuvant Therapy for Early Stage, HER2+ Breast Cancer:
What is the Standard of Care?
Eric Winer, MD; Dana-Farber/Brigham and Women's Cancer Center
10:10 – 10:40 Management of Subcentimeter Breast Cancers
Sara Tolaney, MD, MPH;
Dana-Farber/Brigham and Women's Cancer Center
10:40 – 10:55 Q&A
10:55 – 11:10 Break
11:10 – 11:55 Schlager Lecture: "Triple Negative Breast Cancer Subtypes"
Lisa Carey, MD; University of North Carolinal
11:55 – 12:10 Grab Lunch
12:10 – 1:10 Tumor Board: Local-Regional Therapy for Breast Cancer
Moderator: Mehra Golshan, MD, FACS; Dana-Farber/Brigham and Women's Cancer Center
1:10 – 1:25 Break
1:25 – 3:50 Session VI: Novel Insights in ER+ Breast Cancer
Moderator: Nikhil Wagle, MD; Dana-Farber/Brigham and Women's Cancer Center
1:25 – 1:55 CDK-Inhibitors and Other Novel Approaches for ER+ Breast Cancer
Erica Mayer, MD, MPH;
Dana-Farber/Brigham and Women's Cancer Center
1:55 – 2:25 ER Mutations and their Significance in Breast Cancer
Rinath Jeselsohn, MD;
Dana-Farber/Brigham and Women's Cancer Center
2:25 – 2:55 Duration of Adjuvant Endocrine Therapy
Harold Burstein, MD, PhD;
Dana-Farber/Brigham and Women's Cancer Center
2:55 – 3:25 Which Patients with ER+ Breast Cancer
Should Receive Adjuvant Chemotherapy?
Nancy Lin, MD; Dana-Farber/Brigham and Women's Cancer Center
3:25 – 3:40 Q&A
3:40 – 3:50 Break
3:50 – 5:35 Session VII: Triple Negative Breast Cancer
Moderator: Ann Partridge, MD, MPH; Dana-Farber/Brigham and Women's Cancer Center
3:50 – 4:20 Natural History: The Timing, Staging, and Targets of Recurrence
Nadine Tung, MD; Beth Israel Deaconess Medical Center
4:20 – 4:50 New Therapeutic Targets for Triple Negative Breast Cancer
Steven Isakoff, MD, PhD; Massachusetts General Hospital Cancer Center
4:50 – 5:20 Platinum for Triple Negative Breast Cancer: Who, When, and How?
William Sikov, MD; Warren Alpert Medical School of Brown University
5:20 – 5:35 Q&A
5:35 Adjourn
SATURDAY, JULY 12, 2014
8:00 – 9:00 Tumor Board/Case Discussion: Early Stage Breast Cancer
Harold Burstein, MD, PhD;
Dana-Farber/Brigham and Women's Cancer Center
9:00 – 9:10 Break
9:10 – 10:55 Session VIII: Genomics
Moderator: Judy Garber, MD, MPH;
Dana-Farber/Brigham and Women's Cancer Center
9:10 – 9:40 Genomic Profiling in Breast Cancer: Where Do We Stand?
Andrea Richardson, MD, PhD; Dana-Farber/Brigham and Women's Cancer Center
9:40 – 10:10 Brca and Beyond: Which Patients, Which Tests?
Judy Garber, MD, MPH; Dana-Farber/Brigham and Women's Cancer Center
10:10 – 10:40 Immunotherapy
F. Stephen Hodi, Jr., MD;
Dana-Farber/Brigham and Women's Cancer Center
10:40 – 10:55 Q & A
10:55 – 11:25 Lecture: Innovations in Management of Inflammatory Breast Cancer
Beth Overmoyer, MD; Dana-Farber/Brigham and Women's Cancer Center
11:25 – 12:25 ASCO Highlights
Harold Burstein, MD, PhD;
Dana-Farber/Brigham and Women's Cancer Center
12:25 – 12:30 Closing Remarks
Harold Burstein, MD, PhD;
Dana-Farber/Brigham and Women's Cancer Center
12:30 Adjourn

*Program changes/substitutions may be made without notice.

REGISTRATION INFORMATION



Class Number #341279

Tuition Fees:
Early registration postmarked on or before May 31, 2014
Physicians: $525 (USD)
Nurse Practitioners, Nurses,
and Allied Health Professionals:$425 (USD)
Residents/Fellows in Training: $450 (USD)

Registration after May 31, 2014:
Physicians: $625 (USD)
Nurse Practitioners, Nurses,
and Allied Health Professionals:$525 (USD)
Residents/Fellows in Training: $525 (USD)

PAYMENT INFORMATION

For specific tuition fees, see the registeration form. Registration by credit card (VISA, MasterCard or American Express) can be made here. Registration by check (draft on a United States bank), please make payable to Harvard Medical School and mail with registration form to Harvard Medical School, P.O. Box 417476, Boston, MA 02241-7476. Telephone or fax registration is not accepted. Registration with cash payment is not permitted. Upon receipt of your paid registration an email confirmation from the HMS-DCE office will be sent to you. Be sure to include an email address that you check frequently. Your email address is used for critical information including registration confirmation, evaluation and certificate.

INQUIRIES

Inquiries should be directed to the above address, made by phone: (617) 384‑8600,
Monday ‑ Friday, 9 AM to 5 PM (EST), or by email: hms‑cme@hms.harvard.edu

ACGME COMPETENCIES

This course is designed to meet one or more of the following Accreditation Council of Graduate Medical Education competencies:

  • Patient Care
  • Medical Knowledge
  • Interpersonal and communication skills
  • Professionalism
  • Systems-based practice

DISCLOSURE POLICY

Harvard Medical School (HMS) adheres to all ACCME Essential Areas, Standards, and Policies. It is HMS's policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.

TUITION REFUND POLICY

A handling fee of $60 is deducted for cancellation. Refund requests must be received by postal mail, email or fax one week prior to this activity. No refunds will be made thereafter.

COURSE LOCATION

All sessions will be held at the Long Wharf Marriott, Boston, MA, 296 State St,
Boston, MA 02109. (Telephone: 617-227-0800)

ACCOMMODATIONS/TRAVEL

A limited number of rooms has been reserved at the Boston Long Wharf Marriott (Telephone: 617-227- 0800) until June 20, 2014. Please identify yourself as a "Breast Cancer Course" attendee and provide the Group Code to receive the reduced room rate of $295 per night Single/Double. Hotel arrangements can also be made online at: http://www.marriott.com/hotels/travel/boslw-boston-marriott-long-wharf/. Provide the Group Code bccbcca to receive the reduced room rate. Please do not purchase nonrefundable airline ticket(s) until you have received an email from our office confirming your paid registration. For airline reservations contact the HMS Travel Desk toll free 1-877-4- HARV MD (1-877-442-7863) Monday - Friday 9 AM - 8 PM (EST ). From outside the U.S., Canada and Virgin Islands, please call 617- 559-3764.



Course #341279





Offered by


Course Directors
Harold J. Burstein, MD, PhD
Judy E. Garber, MD, MPH
Barbara L. Smith, MD, PhD
Eric P. Winer, MD

No time to register now? Add your name to the mailing list to receive future notices about this course!



FACULTY

Harvard Medical School
COURSE DIRECTORS

Harold J. Burstein, MD, PhD
Susan F. Smith Center for Women's Cancers, Dana-Farber/Brigham and Women's Cancer Center
Associate Professor of Medicine, Harvard Medical School

Judy E. Garber, MD, MPH
Director, Cancer Genetics and Prevention Clinic, Susan F. Smith Center for Women's Cancers,
Dana-Farber/Brigham and Women's Cancer Center, Professor of Medicine, Harvard Medical School

Barbara L. Smith, MD, PhD
Director, Breast Program, Massachusetts General Hospital Cancer Center
Associate Professor of Surgery, Harvard Medical School

Eric P. Winer, MD
Chief, Division of Women's Cancers; Director, Breast Oncology Center Susan F. Smith Center for Women's Cancers, Dana-Farber/Brigham and Women's Cancer Center
Professor of Medicine,
Harvard Medical School


Susan F. Smith Center for Women's Cancers,
Dana-Farber/Brigham and Women's Cancer Center
Faculty


Craig A. Bunnell, MD, MPH, MBA
Wendy Y. Chen, MD, MPH
Rinath M. Jeselsohn, MD
Shom Goel, MD, PhD
Ian E. Krop, MD, PhD
Jennifer A. Ligibel, MD
Nancy U. Lin, MD
Erica L. Mayer, MD, MPH
Beth Overmoyer, MD
Ann H. Partridge, MD, MPH
Lawrence N. Shulman, MD
Sara M. Tolaney, MD, MPH
Nikhil Wagle, MD

Additional Dana-Farber/Brigham and Women's Cancer Center Faculty
Janet L. Abrahm, MD
Jennifer R. Bellon, MD
Pamela J. DiPiro, MD
Mehra Golshan, MD, FACS
F. Stephen Hodi, Jr., MD
Hadine Joffe, MD, MSc
Mary-Ellen Meadows, PhD
Andrea L. Richardson, MD, PhD

Massachusetts General Hospital Cancer Center
Faculty
Alphonse G. Taghian, MD
Lidia Schapira, MD
Steven Isakoff, MD, PhD


Guest Faculty

William F. Anderson, MD, MPH National Cancer Institute

Lisa A. Carey, MD
University of North Carolina

Shelley Hwang, MD
Duke Medical Center

Monica Morrow, MD, FACS
Memorial Sloan-Kettering
Cancer Center

Abram Recht, MD
Beth Israel Deaconess
Medical Center

Stuart Schnitt, MD
Beth Israel Deaconess
Medical Center

William Sikov, MD
Warren Alpert Medical
School of Brown University

Nadine M. Tung, MD
Beth Israel Deaconess
Medical Center

Antonio C. Wolff, MD
Johns Hopkins Medicine

 

  Copyright © 2014, Harvard Medical School, Department of Continuing Education
    Last update 4.2.2014